Teva Pharmaceutical Industries Limited revenue by year
Over the 10 fiscal years shown, revenue went from $21.90B (year ended Dec 31, 2016) to $17.26B (year ended Dec 31, 2025), a compound annual growth rate of -2.6%. The fastest growth was +6.2% in the year ended Dec 31, 2023; the weakest year was −16.4% (year ended Dec 31, 2018).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $17.26B | +4.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 3, 2026 |
| Dec 31, 2024 | $16.54B | +4.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 3, 2026 |
| Dec 31, 2023 | $15.85B | +6.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 3, 2026 |
| Dec 31, 2022 | $14.93B | −6.0% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 5, 2025 |
| Dec 31, 2021 | $15.88B | −4.7% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 12, 2024 |
| Dec 31, 2020 | $16.66B | −1.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 10, 2023 |
| Dec 31, 2019 | $16.89B | −7.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 9, 2022 |
| Dec 31, 2018 | $18.27B | −16.4% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 10, 2021 |
| Dec 31, 2017 | $21.85B | −0.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 21, 2020 |
| Dec 31, 2016 | $21.90B | +11.5% | SalesRevenueNet | 10-K filed Feb 12, 2018 |
Teva Pharmaceutical Industries Limited reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Sep 30, 2026 | $4.39B | −1.9% | 10-Q filed Nov 3, 2026 |
| 3 months ended Jun 30, 2026 | $4.14B | −0.8% | 10-Q filed Jul 29, 2026 |
| 3 months ended Mar 31, 2026 | $3.98B | +2.3% | 10-Q filed Apr 29, 2026 |
| 3 months ended Sep 30, 2025 | $4.48B | +3.4% | 10-Q filed Nov 3, 2026 |
| 3 months ended Jun 30, 2025 | $4.18B | +0.3% | 10-Q filed Jul 29, 2026 |
| 3 months ended Mar 31, 2025 | $3.89B | +1.9% | 10-Q filed Apr 29, 2026 |
| 3 months ended Sep 30, 2024 | $4.33B | +12.5% | 10-Q filed Nov 5, 2025 |
| 3 months ended Jun 30, 2024 | $4.16B | +7.4% | 10-Q filed Jul 30, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 818686 (raw data). Most recent filing in this dataset: 10-Q filed Nov 3, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.